Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “antagonist”

678 pharma patents match "antagonist" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 678
Index total 30,257
Page 16 / 29

Quick answer

This filtered view shows 678 pharmaceutical patents matching "antagonist" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

678 results for “antagonist” · 30,257 patents in full index Clear search

  1. US 8629141

    Spiro-oxindole MDM2 antagonists

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jan 14, 2014 · Expires Jan 9, 2034

    granted

  2. US 8628764

    Biocontrol of storage maladies of potatoes by bacterial antagonists produced in co-culture

    The United States of America, as represented by the Secretary of Agriculture · Granted Jan 14, 2014 · Expires Jan 9, 2034

    granted

  3. US 8617530

    Polymer conjugates of opioid antagonists

    Nektar Therapeutics · Granted Dec 31, 2013 · Expires Dec 26, 2033

    granted

  4. US 8609395

    Agonist and antagonist peptides of carcinoembryonic antigen (CEA)

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 17, 2013 · Expires Dec 12, 2033

    granted

  5. US 8598149

    Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  6. US 8592453

    Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists

    Theravance, Inc. · Granted Nov 26, 2013 · Expires Nov 21, 2033

    granted

  7. US 8592402

    Compounds as lysophosphatidic acid receptor antagonists

    AMIRA PHARMACEUTICALS, INC. · Granted Nov 26, 2013 · Expires Nov 21, 2033

    granted

  8. US 8580768

    Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted

  9. US 8569351

    Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activity

    Theravance, Inc. · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  10. US 8557245

    Methods for treating bone cancer by administering a nerve growth factor antagonist antibody

    Regents of the University of Minnesota · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  11. US 8557997

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance, Inc. · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  12. US 8551978

    Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity

    Theravance, Inc. · Granted Oct 8, 2013 · Expires Oct 3, 2033

    granted

  13. US 8541587

    Lysophosphatidic acid receptor antagonists

    AMIRA PHARMACEUTICALS, INC. · Granted Sep 24, 2013 · Expires Sep 19, 2033

    granted

  14. US 8524748

    Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors

    Panmira Pharmaceuticals, LLC · Granted Sep 3, 2013 · Expires Aug 29, 2033

    granted

  15. US 8518984

    Spiro-oxindole MDM2 antagonists

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Aug 27, 2013 · Expires Aug 22, 2033

    granted

  16. US 8518966

    Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

    Theravance, Inc. · Granted Aug 27, 2013 · Expires Aug 22, 2033

    granted

  17. US 8518887

    Method of treating cancer with DLL4 antagonist and chemotherapeutic agent

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 27, 2013 · Expires Aug 22, 2033

    granted

  18. US 8507536

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Neurocrine Biosciences, Inc. · Granted Aug 13, 2013 · Expires Aug 8, 2033

    granted

  19. US 8501776

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance, Inc. · Granted Aug 6, 2013 · Expires Aug 1, 2033

    granted

  20. US 8501959

    Cycloalkane[B]indole antagonists of prostaglandin D2 receptors

    Panmira Pharmaceuticals, LLC · Granted Aug 6, 2013 · Expires Aug 1, 2033

    granted

  21. US 8497381

    Antagonists of prostaglandin D2 receptors

    Panmira Pharmaceuticals, LLC · Granted Jul 30, 2013 · Expires Jul 25, 2033

    granted

  22. US 8497287

    Aminotetralin compounds as mu opioid receptor antagonists

    Theravance, Inc. · Granted Jul 30, 2013 · Expires Jul 25, 2033

    granted

  23. US 8492399

    3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists

    Theravance, Inc. · Granted Jul 23, 2013 · Expires Jul 18, 2033

    granted

  24. US 8492407

    Quaternary ammonium compounds useful as muscarinic receptor antagonists

    Theravance, Inc. · Granted Jul 23, 2013 · Expires Jul 18, 2033

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.